Dr Reddy's Shares Tumble 6% After Semaglutide Supply Delay; Quality Issue Clouds Obesity Drug Rollout 

Mumbai, July 9: Dr Reddy’s Laboratories share price slumped as much as 6% on Thursday after the drugmaker announced a delay in the commercial supply of its semaglutide product due to a quality issue linked to the active pharmaceutical ingredient (API), raising concerns over the near-term growth prospects of one of its most anticipated product launches. 

 The stock was one of the top laggards on the Nifty Pharma index. As of writing the stock was down 5.8% at Rs 1,271.  

API quality issue delays commercial supplies 

In an exchange filing, Dr Reddy’s said certain batches of semaglutide were found to be “out of specification” due to an issue associated with the active pharmaceutical ingredient used in the product. 

As a result, the company has decided to delay commercial supplies while it investigates the root cause and undertakes corrective measures to ensure product quality.

The stock fell as the company announced an active ingredient issue with its hotly anticipated drug. Source: NSE 

The Hyderabad-based drugmaker, however, stressed that the issue does not affect patient safety and has no impact on its existing global regulatory filings. The company did not disclose how long the supply disruption would last or provide details on the volume of batches affected.  

Semaglutide seen as key growth driver 

The delay has disappointed investors because semaglutide is widely regarded as one of the pharmaceutical industry’s biggest growth opportunities. 

Semaglutide is the active ingredient in Novo Nordisk’s blockbuster diabetes and obesity drugs Ozempic and Wegovy. Following the expiry of key patents in India earlier this year, several domestic drugmakers have launched lower-cost generic versions to tap into the rapidly expanding market for GLP-1 therapies. 

Dr Reddy’s entered the segment earlier this year with its semaglutide brand Obeda, joining rivals including Zydus Lifesciences in a market that is expected to witness intense competition over the coming years.  

Growth momentum faces near-term setback

Analysts said the supply disruption could temporarily delay the revenue ramp-up expected from semaglutide, even though the company has maintained that there are no safety concerns. 

The obesity and diabetes treatment market has emerged as one of the fastest-growing segments in global pharmaceuticals, with generic manufacturers racing to capture market share following patent expiries. 

Indian companies have launched their products at prices significantly below Novo Nordisk’s branded medicines, making the therapy accessible to a much larger patient base. Dr Reddy’s was expected to be among the key beneficiaries of this opportunity, making Thursday’s announcement a negative surprise for investors.  

Quality remains the immediate priority 

The company said it is conducting a detailed investigation to identify the source of the API-related issue and has initiated measures to ensure all future commercial batches meet quality specifications. 

By voluntarily delaying supplies, Dr Reddy’s appears to be prioritising product quality and regulatory compliance over a hurried commercial rollout. 

The company has not indicated when supplies will resume, suggesting that commercial availability will depend on the completion of the ongoing quality review and corrective actions.

Competitive landscape intensifies 

The delay comes at a time when competition in India’s semaglutide market is heating up. 

Several domestic pharmaceutical companies, including Sun Pharma, Zydus Lifesciences, Glenmark, Torrent Pharmaceuticals, Alkem Laboratories and others, have launched or announced generic semaglutide products following the patent expiry. 

With multiple players competing aggressively on pricing and distribution, any delay in commercial supplies could temporarily affect Dr Reddy’s ability to capture market share in the fast-growing GLP-1 segment. At the same time, analysts believe the long-term opportunity remains intact given the enormous unmet demand for diabetes and obesity treatments in India and overseas.  

Investors await clarity 

Market participants will now look for greater clarity from the company on the duration of the supply disruption, the financial impact of the delay and the timeline for restarting commercial supplies. 

While management has ruled out any impact on patient safety or regulatory filings, investors are expected to closely monitor updates on manufacturing quality and execution, particularly because semaglutide is viewed as a key contributor to Dr Reddy’s future growth strategy. 

For now, the API-related issue has overshadowed the company’s long-term prospects in the high-growth obesity drug market, triggering a sharp correction in the stock despite continued optimism over the broader opportunity offered by GLP-1 therapies. 

Source:

• https://www.nseindia.com/get-quote/equity/DRREDDY/Dr.-Reddy’s-Laboratories-Limited